Connect your AI

AngioDynamics ANGO Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

TFX

TeleflexTFX

$0-100%

MedtronicMDT

——

HaemoneticsHAE

——

GE HealthCare TechnologiesGEHC

——

NordsonNDSN

——

Other financials

Income statement

Revenue$78.4M+8.9%

Gross profit$41.5M+6.7%

Operating income-$13.0M-29.8%

Net income-$8.1M-83.4%

EPS (diluted)-$0.19-72.7%

Balance sheet

Cash & equivalents$37.8M-15.5%

Total debt$7.9M+10.2%

Total equity$173.4M-6.7%

Total assets$260.7M-8.7%

Cash flow

Operating cash flow-$3.1M+76.4%

CapEx$1.0M-43.5%

Free cash flow-$4.1M+72.4%

Valuation

Market cap$564.42M+38.7%

Enterprise value$534.51M+48.0%

P/S1.8×+0.4×

Profitability

Gross margin54.3%-0.1pp

Operating margin-11.3%-2.9pp

Net margin-10%-2.4pp

FCF margin5.5%—

Returns & leverage

Return on equity-17.5%-2.2pp

Debt / equity0×0.0×

Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AngioDynamics's payments for repurchase of common stock?: AngioDynamics (ANGO) reported payments for repurchase of common stock of $0 in Q4 2025.